Vera Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Vera Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| operating expenses: | ||||||||||||||||||
| research and development | 58,195,000 | 41,278,000 | 33,347,000 | 40,314,000 | 29,311,000 | 23,200,000 | 20,785,000 | 16,100,000 | 16,231,000 | 25,108,000 | 26,676,000 | 19,656,000 | 10,112,000 | 12,549,000 | 12,753,000 | 3,564,000 | 3,235,000 | 2,932,000 |
| general and administrative | 21,946,000 | 15,916,000 | 15,567,000 | 9,487,000 | 8,032,000 | 7,912,000 | 6,243,000 | 5,656,000 | 5,739,000 | 6,150,000 | 6,905,000 | 5,588,000 | 4,945,000 | 4,472,000 | 3,832,000 | 3,688,000 | 2,614,000 | 1,784,000 |
| total operating expenses | 80,141,000 | 57,194,000 | 48,914,000 | 49,801,000 | 37,343,000 | 31,112,000 | 27,028,000 | 21,756,000 | 21,970,000 | 31,258,000 | 33,581,000 | 25,244,000 | 15,057,000 | 17,021,000 | 16,585,000 | 7,252,000 | 5,849,000 | 4,716,000 |
| income from operations | -80,141,000 | -57,194,000 | -48,914,000 | -49,801,000 | -37,343,000 | -31,112,000 | -27,028,000 | -21,756,000 | -21,970,000 | -31,258,000 | -33,581,000 | -25,244,000 | -15,057,000 | -17,021,000 | -16,585,000 | -7,252,000 | -5,849,000 | -4,716,000 |
| yoy | 114.61% | 83.83% | 80.98% | 128.91% | 69.97% | -0.47% | -19.51% | -13.82% | 45.91% | 83.64% | 102.48% | 248.10% | 157.43% | 260.92% | ||||
| qoq | 40.12% | 16.93% | -1.78% | 33.36% | 20.03% | 15.11% | 24.23% | -0.97% | -29.71% | -6.92% | 33.03% | 67.66% | -11.54% | 2.63% | 128.70% | 23.99% | 24.02% | |
| operating margin % | ||||||||||||||||||
| other income: | ||||||||||||||||||
| interest income | 6,320,000 | 6,906,000 | 6,663,000 | 4,761,000 | 5,104,000 | 4,186,000 | 1,960,000 | 2,158,000 | 2,239,000 | 1,623,000 | 894,000 | 567,000 | 263,000 | 26,000 | 6,000 | 5,000 | 2,000 | 2,000 |
| interest expense | -1,874,000 | -1,792,000 | -1,871,000 | -1,936,000 | -1,912,000 | -1,906,000 | -1,056,000 | -943,000 | -914,000 | -874,000 | -599,000 | -147,000 | -128,000 | -118,000 | ||||
| other income | -836,000 | 386,000 | 698,000 | 344,000 | 450,000 | 453,000 | 472,000 | 452,000 | 511,000 | 441,000 | 912,000 | 347,000 | 325,000 | 315,000 | ||||
| total other income | 3,610,000 | 5,500,000 | 5,490,000 | 3,169,000 | 3,635,000 | 2,729,000 | 1,374,000 | 1,652,000 | 1,808,000 | 1,189,000 | 1,143,000 | 565,000 | 204,000 | -64,000 | -261,000 | -359,000 | 2,412,000 | 2,000 |
| net income | -76,531,000 | -51,694,000 | -43,425,000 | -46,632,000 | -33,708,000 | -28,383,000 | -25,655,000 | -20,104,000 | -20,162,000 | -30,069,000 | -32,439,000 | -24,679,000 | -14,853,000 | -17,085,000 | ||||
| yoy | 127.04% | 82.13% | 69.27% | 131.95% | 67.19% | -5.61% | -20.91% | -18.54% | 35.74% | 76.00% | ||||||||
| qoq | 48.05% | 19.04% | -6.88% | 38.34% | 18.76% | 10.63% | 27.61% | -0.29% | -32.95% | -7.31% | 31.44% | 66.15% | -13.06% | |||||
| net income margin % | ||||||||||||||||||
| other comprehensive loss: | ||||||||||||||||||
| change in unrealized gains and losses on marketable securities | -127,000 | 261,000 | -651,000 | 1,494,000 | ||||||||||||||
| comprehensive loss | -76,658,000 | -51,433,000 | -44,076,000 | -45,138,000 | -33,985,000 | -28,807,000 | -25,553,000 | -20,037,000 | -20,300,000 | -29,849,000 | ||||||||
| net income per share | -1.2 | -0.81 | -0.72 | -0.85 | -0.62 | -0.56 | -0.58 | -0.45 | -0.46 | -0.8 | -1.19 | -0.91 | -0.55 | -0.71 | -0.97 | -0.36 | -0.33 | -12.23 |
| weighted-average shares used for eps calculation | 63,789,303 | 63,671,558 | 55,326,680 | 54,898,297 | 54,728,552 | 50,971,933 | 42,707,072 | 44,363,419 | 44,269,772 | 37,667,566 | 26,570,676 | 27,215,874 | 27,078,450 | 24,227,282 | 13,435,706 | 21,265,519 | 10,499,937 | |
| other comprehensive income: | ||||||||||||||||||
| change in fair value of non-marketable equity securities | -7,000 | -4,000 | -2,000 | -15,000 | -28,000 | -1,000 | -64,000 | -202,000 | -256,000 | -287,000 | -247,000 | -364,000 | -281,000 | |||||
| change in unrealized gain on marketable securities | -277,000 | -424,000 | 220,000 | |||||||||||||||
| change in unrealized loss on marketable securities | 37,250 | 67,000 | -138,000 | 55,000 | -127,000 | -140,000 | -12,000 | |||||||||||
| gain on sale of pnai technology | 2,691,000 | |||||||||||||||||
| total loss and other comprehensive loss | -14,224,000 | -24,806,000 | -14,993,000 | -17,097,000 | ||||||||||||||
| restructuring costs | ||||||||||||||||||
| gain on issuance of convertible notes | ||||||||||||||||||
| change in fair value of convertible notes | ||||||||||||||||||
| net income and comprehensive loss | -16,847,000 | -7,611,000 | -3,437,000 | -4,714,000 | ||||||||||||||
| weighted-average common shares outstanding, basic and diluted | 385,401 |
We provide you with 20 years income statements for Vera Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Vera Therapeutics stock. Explore the full financial landscape of Vera Therapeutics stock with our expertly curated income statements.
The information provided in this report about Vera Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.